Adagio Medical Holdings, Inc. (ADGM) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Adagio Medical Holdings, Inc.'s filing signal turned positive.

Adagio Medical Holdings, Inc. is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias, specifically ventricular tachycardia (VT), using its proprietary Ultra-Low Temperature Ablation (ULTA) technology. Unlike current radiofrequency ablation catheters designed for atrial fibrillation, Adagio's ULTA products, such as the vCLAS Cryoablation System, are purpose-built for the ventricular anatomy, aiming to create larger, more durable lesions. The company has completed enrollment in its FULCRUM-VT pivotal FDA IDE study for the vCLAS system and has obtained CE Mark approval in Europe. Adagio is also developing a next-generation ULTA catheter and a Pulsed Field Cryoablation (PFCA) technology.

Historically, revenue was generated from the sale of catheters and implied rental revenue from consoles loaned to customers. However, the company has paused commercial activities in Europe and did not generate revenue in the year ended December 31, 2025.